Search Results for: the niche

Weekly reads: stem cell niche & AI stumble on health

stem cell niche, klauskaestner

What is a stem cell niche? It’s the home of stem cells. The stem cell niche is a fascinating environment. It has many constituents that impact stem cell behavior and even eventual stem cell transplant functions. In today’s weekly reads, we’ll start with the niche as there have been several interesting papers on this topic. The

Weekly reads: stem cell niche & AI stumble on health Read More »

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more

Senolytics restore the stem cell niche in the brains of mice. Fatt, et al. Stem Cell Reports 2022.

Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »

Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done”

SCOTS trial

David Weinberg over at Science-Based Medicine has his part two of a deep dive into the so-called SCOTS trial, which is a non-traditional pay-for-play study. I highly recommend it. SCOTS trial under the magnifying glass In this piece, Weinberg provides interesting background on the two people running SCOTS. I’ve had many concerns about the SCOTS

Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done” Read More »

Recommend reads: stem cell niche, Georgia & FTC on clinics, more

Georgia AG Chris Carr

This blog is called The Niche so publications on the stem cell niche often catch my eye even if that’s not something my own lab directly works on much. So today’s recommended reads will start with two papers on the stem cell niche. The first one focused on the niche  gone wrong. The stem cell

Recommend reads: stem cell niche, Georgia & FTC on clinics, more Read More »